

7 August 2024

Multiple Sclerosis Treatments

I have a freedom of information request I would like to raise with the trust. Within your trust, how many patients with Multiple Sclerosis (MS) are currently being treated with the following drugs:

| | Total supplied by BHSCT for BHSCT Residents only | Total Supplied by BHSCT for NON BHSCT Residents | Total Supplied by BHSCT across all Trusts |
|--------------------------------------|---|--|--|
| Aubagio (Teriflunomide) | 42 | 60 | 102 |
| Lemtrada (Alemtuzumab) | < 5 | 0 | < 5 |
| Kesimpta (Ofatumumab) | 14 | 9 | 23 |
| Ocrevus (Ocrelizumab) | 122 | 72 | 194 |
| Tecfidera (Dimethyl fumarate) | 94 | 175 | 269 |
| Tysabri (Natalizumab) | 41 | 59 | 100 |

Use of < 5 (less than five): We are unable to provide an exact figure - exempt from release under section 40(2) of the FOI Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulations 2018.